Sekar Kathiresan is Chief Executive Officer of Verve Therapeutics, Inc. (VERV). The company reported total compensation of $7,442,663 for fiscal year 2024.
| Salary | $639,231 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,683,000 |
| Option awards | $4,727,372 |
| Non-equity incentive plan | $378,972 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,088 |
| Total | $7,442,663 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Verve Therapeutics, Inc. filed April 25, 2025, accession 0000950170-25-058325.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | Chief Executive Officer | $639,231 | $0 | $1,683,000 | $4,727,372 | $378,972 | $0 | $14,088 | $7,442,663 |
| FY2022 | Chief Executive Officer | $571,320 | $0 | $0 | $6,947,166 | $315,744 | $0 | $12,488 | $7,846,718 |
Totals as disclosed in each year's own compensation disclosure for Verve Therapeutics, Inc..
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Sekar Kathiresan this page | Chief Executive Officer | $7,442,663 |
| Andrew Bellinger | Former Chief Scientific Officer | $3,430,900 |
| Allison Dorval | Chief Financial Officer | $2,881,705 |
| Andrew Ashe | President, Chief Operating Officer and General Counsel | $2,380,065 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Verve Therapeutics, Inc. compensation brief.
Sekar Kathiresan's compensation sits inside Verve Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.